Poliovirus Specific Neutra™ Antibody Products

Creative Biolabs provides high-quality Poliovirus antibodies to support your various research applications. Our antibodies are designed to meet the strict requirements of scientific study, delivering reliable and consistent results.

Contact our team to get an inquiry now!

Introduction of Poliovirus

Poliovirus, the etiological agent of poliomyelitis, is a non-enveloped, single-stranded RNA virus whose structural minimalism belies its global public health impact. As a member of the Enterovirus C species (family Picornaviridae), it comprises three antigenically distinct serotypes (PV1–3). The virion’s icosahedral capsid encases a monopartite, positive-sense RNA genome—a simplicity that has rendered it a paradigm for studying (+)ssRNA virus replication dynamics.

Fig. 1 Type 3 poliovirus capsid.Distributed under CC BY-SA 4.0, from Wiki, without modification

Viral entry commences with high-affinity CD155 receptor engagement on permissive cells, inducing capsid rearrangement and genomic RNA release into the cytosol. The 7.4-kb genome is translated via an internal ribosome entry site (IRES) into an autoproteolytically processed polyprotein (P1–P3), yielding structural (VP1–4) and nonstructural (2A–3D) components. Replication occurs via a negative-strand RNA intermediate primed by VPg uridylylation, with progeny virions assembling through co-opted host ESCRT machinery.

Cellular tropism is dictated by CD155 distribution, enabling fecal-oral transmission or oropharyngeal shedding. While ~72% of infections remain subclinical, neuroinvasion triggers anterior horn motor neuron lysis via caspase-3-mediated apoptosis, precipitating flaccid paralysis. Adaptive immunity targets conserved neutralizing antigenic sites (NAg1/3), with both inactivated (IPV) and live-attenuated (Sabin OPV) vaccines inducing humoral immunity through conformation-specific antibody responses to VP1 BC-loop epitopes.

Antibodies against Poliovirus

Antibodies directed against poliovirus are indispensable tools across a spectrum of research and clinical applications. The poliovirus virion, a naked, icosahedral particle sedimenting at 155S, is composed of a single-stranded, plus-sense RNA genome and ca. The immunodominant neutralizing epitopes of poliovirus exhibit spatial convergence with CD155 receptor recognition motifs on the viral capsid surface. Vaccination studies demonstrated exclusive induction of neutralizing titers by native 155S virions and 80S procapsids in murine models. Conversely, SDS-disrupted virion components—including VP1–4 monomers and assembly intermediates —lacked immunogenic capacity. This contrasts sharply with non-enveloped enteroviruses like FMDV, where recombinant VP1 trimers elicit protective immunity, and CBV3, wherein isolated VP2 elicits cross-reactive neutralization.

Published Data

Fig. 2 9H2 Fab binds virus in all three serotypes.¹

The study delineates the cross-serotypic epitope of human mAb 9H2—a pan-poliovirus neutralizing agent—through structural virology approaches. Cryo-electron microscopy reconstructions of 9H2 Fab complexed with PV1, PV2, and PV3 capsids reveal a conserved binding topology: identical orientation angles relative to the virion surface and footprint overlap with the PVR/CD155 receptor interface. The epitope spans the canyon region, a conserved depression near the five-fold axis, without inducing capsid conformational shifts. Competitive BLI assays demonstrate 9H2 displaces soluble PVR, validating receptor mimicry as its neutralization mechanism. This contrasts with other enterovirus-targeting mAbs requiring particle breathing for access. Serotype-agnostic neutralization paired with evolutionary constraint on canyon residues positions 9H2 as a prototype "canyon-locking" biotherapeutic, circumventing antigenic variation challenges plaguing current vaccines.

Why Choose Us?

Creative Biolabs is committed to providing our clients with the highest quality poliovirus antibodies and exceptional service. Our expertise in antibody development, combined with our advanced technology, ensures that we can meet even the most challenging project requirements.

• High-affinity antibodies for specific detection of poliovirus.
• Custom antibody development services tailored to your unique research requirements.
• Antibody characterization and validation services to ensure data reliability.
• Assay development support for poliovirus research.

For more information about Creative Biolabs' poliovirus antibodies and services, please contact us.